Journal article

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial

Martin R Stockler, Rachel O'Connell, Anna K Nowak, David Goldstein, Jane Turner, Nicholas RC Wilcken, David Wyld, Ehtesham A Abdi, Amanda Glasgow, Philip J Beale, Michael Jefford, Haryana Dhillon, Stephane Heritier, Candace Carter, Ian B Hickie, R John Simes



BACKGROUND: Depression, anxiety, fatigue, and impaired wellbeing are common, important, and closely related in advanced cancer. We aimed to identify the effects of an established antidepressant on these symptoms and survival in patients with advanced cancer who did not have major depression as assessed by clinicians. METHODS: Between July, 2001, and February, 2006, 189 patients with advanced cancer were randomly assigned sertraline 50 mg (n=95), or placebo (n=94), once per day. The primary outcome was depression as assessed by the Centre for Epidemiologic Studies Depression scale (CES-D); the main secondary outcomes were: anxiety as assessed by Hospital Anxiety and Depression Scales (HADS-A)..

View full abstract